Macrophage phenotype | inducer | Mechanism of action | Pathway | References |
---|---|---|---|---|
AM | IL-13 | Recruit T cell to lung Levels of IL-4/IL-13↓ | Type-2 immunity | [19] |
ECM | M1 activation↑ Expression of IL-6/TNF-α/IL-1β↑ | NFκB | [20] | |
NLRP3 | Accumulated IL-1β/IL-18 induce TGF-β↑ | NLRP3 | ||
oxidized phospholipids | Increasing abnormal lipid surfactant promoted M2 polarization↑ | Lipids metabolism | [24] | |
ApoE | Expression of Collagen I↑ | LPR1 | [26] | |
IM | TLR4/TLR9 | Increased IL-6/IL-10/IL-1 receptor antagonist↑ | Toll-like receptor | [29] |
CSF1R | Higher level of Arg-1 than AMs↑ | CSF1/CSF1R | [30] | |
M1 | LPS | Secretion of pro-inflammatory IL-6/ TNF-α↑ | LPS/TLR4 | [34] |
MEF2C | Expression of IL-12a/IL-2b↑ | IL-12 | [35] | |
LPS/IL-4 | Gene levels of IL-6/IL-9/IL-15↑ | IL12/Arg | [36] | |
IFN-γ | Gene levels of JAK1/JAK2/TYK2↑ | JAK/STAT | [37] | |
LPS/IFN-γ | Levels of CXCL10, IL-6 and TNFα↑ | JAKs | [38] | |
ROS | Upregulation TGF-β1, Smad2, Smad3, COL1A1, α-SMA, and MMP2↑ Downregulation of Smad7 and TIMP2↓ | TGF-β/Smad2/3 | [42] | |
M2 | TGF-β1 and p-Smad2/3 | Upregulation of TGF-β1 and p-Smad2/3 promotes EMT↑ | TGF-β1/Smad2/3 | |
STAT6 | Upregulation of IL-4, IL-13 and STAT6↑ | IL4/IL-13 | [47] | |
IL-4, 5, and 13 | IL-4, 5, and 13 protein synthesis decrease Arg-1↓ | NKT/Th2 | [48] | |
MMP-10 | Promoted M2 phenotypes with increased collagenase activity↑ | Collagen degradation | [49] | |
MMP-28 | Enhanced IL-6↑ Downregulation of Arg-1 and Ym1↓ | EMT | [50] |